SCHEMBL10586

SCHEMBL10586

Cc1cccc2c1ncn2Cc1oc2ccccc2c(=O)c1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
THRB P10828 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
POLB P06746 2/20 0.39
HTT P42858 2/20 0.39
MAPT P10636 1/20 0.39
CYP19A1 P11511 2/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
LMNA P02545 1/20 0.39
TLR7 Q9NYK1 2/20 0.39
HDAC6 Q9UBN7 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30680212 1.00 ALDH1A1 (0.46) ALDH1A1THRBSMN1; SMN2CA1CA2
SCHEMBL11438 0.88 ALDH1A1 (0.38) ALDH1A1THRBSMN1; SMN2POLBMAPT
SCHEMBL30680216 0.84 CYP11B1 (0.49) ALDH1A1SMN1; SMN2CA1CA2POLB
SCHEMBL9083 0.84 CYP11B1 (0.49) ALDH1A1SMN1; SMN2CA1CA2POLB
SCHEMBL8577 0.76 ADORA2A (0.53) ALDH1A1SMN1; SMN2CA1CA2CYP19A1
SCHEMBL8786 0.76 MEN1 (0.41) ALDH1A1SMN1; SMN2CA1CA2CYP19A1
SCHEMBL29651680 0.76 ADORA2A (0.53) ALDH1A1SMN1; SMN2CA1CA2CYP19A1
SCHEMBL29651707 0.72 CYP11B1 (0.44) ALDH1A1SMN1; SMN2HTTMAPTCYP11B1
SCHEMBL10907 0.72 CYP11B1 (0.44) ALDH1A1SMN1; SMN2HTTMAPTCYP11B1
SCHEMBL29651625 0.71 CYP19A1 (0.69) CYP19A1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 US claimed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US claimed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US claimed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 EP claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
EP-2916868-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR RHIZEN PHARMACEUTICALS S A (CH) 2022-05-11 EP disclosed
US-11065236-B2 Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor RHIZEN PHARMACEUTICALS SA (CH) 2021-07-20 US disclosed
CN-111904962-A Pharmaceutical composition containing PDE4 inhibitor and PI3 or dual PI 3-gamma kinase inhibitor 理森制药股份公司 2020-11-10 CN disclosed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 EP disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ALDH1A1 4305/4885THRB 991/4885SMN1; SMN2 2637/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ALDH1A1 4305/4885THRB 991/4885SMN1; SMN2 2637/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ALDH1A1 4305/4885THRB 991/4885SMN1; SMN2 2637/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A ALDH1A1 3748/4885THRB 1057/4885SMN1; SMN2 2484/4885
US-11065236-B2 Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor PIK3CD, PIK3R4, PIK3CG ALDH1A1 2578/4885THRB 1556/4885SMN1; SMN2 4591/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ALDH1A1 4305/4885THRB 991/4885SMN1; SMN2 2637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.